Endonovo Therapeutics, Inc.
ENDV
$0.0002
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 255.70K | 265.20K | 220.70K | 135.50K | 14.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 255.70K | 265.20K | 220.70K | 135.50K | 14.30K |
| Cost of Revenue | 9.70K | 12.90K | 13.30K | 10.00K | 14.00K |
| Gross Profit | 246.00K | 252.20K | 207.30K | 125.40K | 300.00 |
| SG&A Expenses | 2.86M | 2.89M | 3.52M | 3.39M | 3.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.87M | 2.91M | 3.53M | 3.40M | 3.17M |
| Operating Income | -2.62M | -2.64M | -3.31M | -3.26M | -3.16M |
| Income Before Tax | -4.40M | -4.24M | -8.83M | -18.47M | -3.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.40 | -4.24 | -8.83 | -18.47 | -3.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.40M | -4.24M | -8.83M | -18.47M | -3.15M |
| EBIT | -2.62M | -2.64M | -3.31M | -3.26M | -3.16M |
| EBITDA | -1.97M | -1.99M | -2.66M | -2.62M | -2.51M |
| EPS Basic | -0.03 | -0.04 | -0.06 | -0.12 | -0.02 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.04 | -0.08 | -0.01 |
| EPS Diluted | -0.07 | -0.07 | -0.09 | -0.12 | -0.02 |
| Normalized Diluted EPS | -0.04 | -0.04 | -0.06 | -0.08 | -0.01 |
| Average Basic Shares Outstanding | 1.02B | 870.50M | 728.53M | 556.18M | 440.40M |
| Average Diluted Shares Outstanding | 3.58B | 3.44B | 2.22B | 556.18M | 440.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
